BACKGROUND: Preeclampsia and fetal growth restriction are considered to be placentally mediated disorders. The clinical manifestations are widely held to relate to gestation age at onset with early-and late-onset preeclampsia considered to be phenotypically distinct. Recent studies have reported conflicting findings in relation to cardiovascular function, and in particular cardiac output, in preeclampsia and fetal growth restriction. OBJECTIVE: We conducted this study to examine the possible relation between cardiac output and peripheral vascular resistance in preeclampsia and fetal growth restriction. STUDY DESIGN: We investigated maternal cardiovascular function in relation to clinical subtype in 45 pathological pregnancies (14 preeclampsia only, 16 fetal growth restriction only, 15 preeclampsia and fetal growth restriction) and compared these with 107 healthy person observations. Cardiac output was the primary outcome measure and was assessed using an inert gas-rebreathing method (Innocor), from which peripheral vascular resistance was derived; arterial function was assessed by Vicorder, a cuffbased oscillometric device. Cardiovascular parameters were normalized for gestational age in relation to healthy pregnancies using Z scores, thus allowing for comparison across the gestational range of 24e40 weeks. RESULTS: Compared with healthy control pregnancies, women with preeclampsia had higher cardiac output Z scores (1.87 AE 1.35; P ¼ .0001) and lower peripheral vascular resistance Z scores (e0.76 AE 0.89; P ¼ .025); those with fetal growth restriction had higher peripheral vascular resistance Z scores (0.57 AE 1.18; P ¼ .04) and those with both preeclampsia and fetal growth restriction had lower cardiac output Z scores (e0.80 AE 1.3 P ¼ .007) and higher peripheral vascular resistance
Z scores (2.16 AE 1.96; P ¼ .0001). These changes were not related to gestational age of onset. All those affected by preeclampsia and/or fetal growth restriction had abnormally raised augmentation index and pulse wave velocity. Furthermore, in preeclampsia, low cardiac output was associated with low birthweight and high cardiac output with high birthweight (r ¼ 0.42, P ¼ .03). CONCLUSION: Preeclampsia is associated with high cardiac output, but if preeclampsia presents with fetal growth restriction, the opposite is true; both conditions are nevertheless defined by hypertension. Fetal growth restriction without preeclampsia is associated with high peripheral vascular resistance. Although early and late gestation preeclampsias are considered to be different diseases, we show that the hemodynamic characteristics of preeclampsia were unrelated to gestational age at onset but were strongly associated with the presence or absence of fetal growth restriction. Fetal growth restriction more commonly coexists with preeclampsia at early gestation, thus explaining the conflicting results of previous studies. Furthermore, antihypertensive agents act by reducing cardiac output or peripheral vascular resistance and are administered without reference to cardiovascular function in preeclampsia. The underlying pathology (preeclampsia, fetal growth restriction, preeclampsia and fetal growth restriction) defines cardiovascular phenotype, providing a rational basis for choice of therapy in which high or low cardiac output or peripheral vascular resistance is the predominant feature.
Key words: arterial function, cardiac output, hypertension, pregnancy, vascular resistance P reeclampsia (PE) is not simply a pregnancy-specific syndrome: its implications on later life cardiovascular 1 and cognitive function 2 and health care cost 3 are only now being understood. Fetal growth restriction (FGR) has a close but poorly understood relationship with PE.
Although PE and FGR frequently present in isolation, they may occur together, particularly at early gestation. 4 The underlying pathophysiology of PE has never been fully understood, but the cause has often been attributed to the placenta because PE resolves completely after delivery. Inadequate trophoblast invasion leading to uteroplacental malperfusion is thought to underlie both PE and FGR. 5, 6 However, this placental theory does not explain why women who had PE in their pregnancies have a higher cardiovascular risk in later life [7] [8] [9] or why women with prepregnancy cardiovascular risk factors have a higher risk of PE and FGR in pregnancy. 10 Emerging data suggest that maternal cardiovascular function is impaired after delivery in women with PE, 11, 12 and high blood pressure prior to pregnancy increases the risk of PE developing. 10 Nevertheless, PE and FGR are commonly referred to as placenta-mediated disorders, suggested to arise through defective placentation.
Studies of cardiovascular function in pregnancy have shown inconsistent and, in some cases, contradictory results. The classic studies of Easterling et al 13 suggested that PE was associated with a high cardiac output (CO) state, although this relationship was thought to be explained, at least in part, by the increased body surface area. 14 Other studies have suggested that PE should be subdivided into those in which low or high CO is predominant. 15 FGR with and without PE have a different cardiovascular profile 16, 17 although the relationship of these changes to a healthy pregnancy or PE without FGR has not been studied. A recent systematic review concluded that studies of cardiovascular function in gestational hypertension and PE show conflicting results. The authors concluded that "increased peripheral vascular resistance correlates with disease severity," but of note, the coexistence of FGR was not considered in a majority of the studies. 18 Previous studies on cardiovascular function in PE have incompletely characterized FGR, 19 recruited only within a particular gestational range 16 and/or not compared findings with a healthy reference pregnant population. 20 Existing studies provide interesting insights to cardiovascular dysfunction in pathological pregnancies but leave important questions unanswered in relationship with gestational effects and pregnancies in which PE and FGR are combined.
Over the last 2 decades, it has become customary to subdivide PE into early and late variants with an arbitrary 34 week gestational age cutoff. This distinction arose not because of a pathophysiological difference between the conditions but because of the inability of screening by uterine artery Doppler to effectively identify cases of late-onset disease. [21] [22] [23] It is suggested that early and late variants have different underlying vascular characteristics, although in most studies, late PE is rarely or never associated with FGR. 20 Adding further complexity, recent studies have suggested that PE at term is associated with babies with larger birthweight. 14 We sought to investigate the relationship between cardiovascular function and clinical phenotype of PE and FGR alone and in combination across a gestation range, with cardiac output being the primary outcome measure. Cardiovascular function changes with gestational age, therefore, to allow comparison, we transformed all data in relation to that obtained from women with healthy pregnancies using the statistical technique of Z scoring. This removed the need for a gestation-matched cohort design and allowed all data points to be considered. 19 In doing so, we performed comprehensive hemodynamic assessments from 24 weeks' gestation onward in women with healthy pregnancies, with PE in combination with FGR (PE and FGR), PE without FGR (PE only), and FGR without PE (FGR only), managed and monitored in a single maternity unit.
Materials and Methods

Study protocol
In this prospective cross-sectional study, women between weeks 24 and 40 of pregnancy were recruited from the antenatal clinic, labor ward, day assessment unit, and antenatal ward of a tertiary-level London teaching hospital between January 2015 and May 2017. The study protocol was approved by National Health Service National Research Ethics Committee, London Riverside, and all participants gave written informed consent. Gestation of pregnancy was determined by measurement of crown-rump length between 11 and 13 weeks in early pregnancy.
Women were recruited at presentation or diagnosis where it was feasible to conduct a detailed cardiovascular examination and were not included if they were already in labor, undergoing induction of labor, or imminent delivery was planned (Figure 1) . We describe the diagnosis as those with PE alone (PE only), FGR alone (FGR only), and PE together with FGR (PE and FGR). Women's assessments are reported at the time of initial diagnosis of 1 of these conditions, and the diagnosis assigned at the time of study inclusion.
One hundred seven healthy person observations acted as control cases with no control subject assessed twice within the same epoch. PE was defined as blood pressure at diagnosis of >140/90 mm Hg and urine protein creatinine ratio of >30.
FGR was defined as fetal abdominal circumference or estimated fetal weight <10th centile 24 and umbilical Doppler PI >95th centile on ultrasound scan. 25 Those women with known underlying cardiovascular conditions, multiple pregnancies, and fetal anomalies were excluded from the study.
Participants underwent peripheral blood pressure measurement, comprehensive cardiovascular assessments, and fetal ultrasound scans as detailed in the following text.
Cardiovascular assessments
Participants were requested to abstain from caffeinated drinks for 4 hours before the visit. In brief, cardiovascular AJOG at a Glance Why was this study conducted? To resolve the unanswered questions as to the precise hemodynamic changes in pregnancies complicated by preeclampsia, fetal growth restriction, and the combination of the 2 and whether gestation at onset determines these changes.
Key Findings
In preeclampsia, cardiac output is high and peripheral resistance low. In fetal growth restriction with preeclampsia, the opposite is true, and in growth restriction, there is increased peripheral resistance. Arterial function is abnormal in all cases.
What does this add to what is known?
Preeclampsia and fetal growth restriction are associated with distinctly different and opposing cardiovascular phenotypes that are not related to gestation of onset. These findings may be important in monitoring maternal and fetal condition and guiding therapy.
Original Research OBSTETRICS ajog.org measurements were performed with the patient standing upright for the assessment of cardiac output and in the left lateral lying position for assessment of arterial function. Cardiac output was measured using Innocor, a noninvasive inert gas-rebreathing technique as previously described. 26, 27 Brachial blood pressure was measured using Omron M-7 (OMRON Healthcare Europe B.V., Hoofddorp, Netherlands), which has been validated in pregnancy. 28 Blood pressure was measured on the right arm in the seated position following recommendations from the European ajog.org
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Society of Hypertension. 29 Mean arterial pressure was calculated by (diastolic pressure þ [systolic pressure e diastolic pressure)/3]). Peripheral vascular resistance (PVR) was derived with the following formula: PVR ¼ mean arterial pressure Â 80/cardiac output.
Arterial analysis was performed using the Vicorder (Skidmore Medical, Bristol, United Kingdom), an oscillometric device validated for the measurements of augmentation index (AIx) and pulse wave velocity (PWV). 30 With the patient lying in the left lateral position, a brachial cuff was applied to the right upper arm, a leg cuff applied to the right upper thigh, and a neck sensor positioned over the carotid artery. A standard measuring tape was used to measure the linear distance between the suprasternal notch and a defined point on the femoral cuff. The AIx, PWV, and maternal heart rate (beats per minute) were recorded.
Ultrasound
Obstetric ultrasound assessment was performed on Samsung WS80 equipment (Samsung Medison, Seoul, Republic of Korea). Fetal growth parameters (head circumference, biparietal diameter, abdominal circumference, and femur length) and Doppler studies (umbilical, middle cerebral artery, ductus venosus, and uterine artery) were recorded in all pathological pregnancy cases.
Statistical analysis
Statistical analyses were performed using SPSS (version 24-0-0, 2016; SPSS Inc, Chicago, IL). The Kruskal-Wallis test was used to compare the demographic characteristics between the 4 groups. The normality of distribution of the data was examined with the Shapiro-Wilk test, and histograms and data are expressed as means AE SD or medians (interquartile range) for normally and nonnormally distributed data, respectively. We analyzed the data using body mass index, age, and ethnicity as covariates. Because cardiovascular function changes with gestational age and to compare hemodynamic characteristics across groups with different gestational ages, we transformed all data in relation to that obtained from women with healthy pregnancies using the statistical technique of Z scoring. This removed the need for a gestation-matched cohort design and allowed all data points to be considered. 16 Briefly
þ6 weeks) for CO, PVR, Aix, and PWV. The Z scores of each cardiovascular parameter were then compared using an unpaired Student t test. In our cohort, heart rate did not change with gestation and comparisons were made with untransformed data.
Results
Forty-five pathological pregnancies (14 PE only, 16 FGR only, and 15 PE and FGR) were recruited, of whom 3 had a prior history of PE and/or FGR. All women remained within the category to which they were first assigned at recruitment. A further 64 women with healthy pregnancies and normal pregnancy outcomes were studied across the gestation, yielding 107 healthy pregnancy observations.
A Kruskal-Wallis test showed no statistically significant differences between age and ethnicity within the 4 groups. The group with PE had a higher booking body mass index when compared with the control group (P ¼ .001) ( Table 1) .
Cardiovascular parameters in pathological and control groups are presented in Table 2 . The cardiovascular parameters in pathological pregnancies are presented in Table 3 ; Z scores were calculated in relation to control cases from healthy pregnancies, which were subdivided into 4 weekly gestational epochs.
FGR only
In women with FGR only, PVR Z score was significantly higher (0.57 AE 1.18, P ¼ .04) (Figure 2) , and the CO Z score was no different from healthy controls (e0.35 AE 0.99, P ¼ .19) (Figure 3) . The Z scores of AIx (1.18 AE 1.44, P ¼.0001) (Figure 4 ) and PWV (0.87 AE 1.34, P ¼ .002) ( Figure 5 ) were higher than controls.
PE only
Women with PE only had a higher CO Z score than controls 1.87 AE 1.35, Of the 13 women with PE only, 7 women were examined before starting antihypertensive medication, 3 women were on labetalol, and 1 on nifedipine. The Z scores for CO and PVR of those examined on treatment vs those without were not different (P ¼ 0.55 and P ¼.57, respectively).
PE and FGR
In PE and FGR cases, a lower CO Z score (e0.80 AE 1.3, P ¼ .007) ( Figure 3 ) and a higher PVR Z score (2.16 AE 1.95, P ¼ .0001) ( Figure 2 ) were observed compared with controls. There was a higher AIx Z score (1.45 AE 1.09, P ¼ .0001) ( Figure 4 ) and a higher PWV Z score (2.01 AE 1.55, P ¼.0001) ( Figure 5 ).
Of the 14 women with PE and FGR, 3 were examined before starting antihypertensive medication, and 4 were taking labetalol, 2 nifedipine, and 3 both labetalol and nifedipine. Comparing the Z scores for CO and PVR of those examined on treatment vs those without, there were no differences (P ¼ .52 and P ¼ .99, respectively).
Heart rate
There was no difference in observed heart rate between the 4 groups. (P ¼ .26) (Figure 6 ).
Gestation vs CO/PVR
When compared across gestation (decimal weeks by estimated due date derived from dating scan), there was no relationship between gestation and either CO Z score (Pearson correlation, 0.16, P ¼ .35) or PVR Z score (Pearson correlation, e0.21, P ¼.2) for PE only, FGR only, and PE and FGR.
There was no difference between CO Z score (P ¼ .41) or PVR Z score (P ¼ .18) in PE only prior to 34 weeks and those after 34 weeks. In combined PE and FGR cases, there was again no difference between CO Z score (P ¼ .34) or PVR Z score (P ¼.76) in cases prior to 34 weeks and those after.
CO vs Z score birthweight
Within the group of women with PE (PE only and PE and FGR), CO was positively associated with Z score birthweight (r ¼ 0.42, P ¼ .03). Within the group of women with FGR only, CO was not associated with Z score birthweight (r ¼ 0.27, P ¼ .31).
Post hoc power calculation
Because this was novel work, a formal sample size calculation prior to undertaking the study was not possible, and the enrollment period was guided by our previous prepregnancy studies in healthy women. 27, 31, 32 However, a formal post hoc power calculation, assuming 4 unequal groups and an SD for the CO Z score equivalent to the highest SD obtained in the 3 pathological pregnancy groups, gave >98% power to detect a significant overall difference in CO Z score, at an alpha level of 0.05.
Comment
We report that women with PE only, FGR only, and PE and FGR have distinctly different and, in some cases, opposing cardiovascular characteristics. The predominant abnormalities in PE only were a higher CO and lower PVR, while FGR only was characterized by higher PVR than healthy pregnancies. When both PE and FGR occur together, the effect was a cardiovascular phenotype characterized by a markedly higher PVR and lower CO than FGR only.
Previous studies of PE and FGR have reported inconsistent findings; however, none have studied hemodynamic findings across the whole gestation range in relation to healthy pregnancies recruited concurrently nor have considered FGR, PE, and PEFGR as separate entities.
Recently a meta-analysis by Castleman et al 18 found that in gestational hypertensive diseases, "severity of disease corresponded with increasing vascular resistance." We suggest that this is an oversimplification in that according to our data, it holds for PE with FGR, the converse being true for PE not affected Original Research OBSTETRICS ajog.org by FGR. 18 Irrespective of differences in CO and PVR, all 3 pregnancy complications were associated with abnormal arterial function assessed by increased augmentation index and increased pulse wave velocity.
The implications for understanding of the disease process is important, particularly in respect of the deeply ingrained but empirical and arbitrary distinction between early and late PE with a cutoff at 34 weeks. 22, 33 It is true that the cardiovascular features of early and late PE were different, but this was purely by virtue of the association with FGR rather than because of the gestational age at onset of the disease.
PE only had the same cardiovascular findings (high CO and low PVR) at early and late gestational ages, but if PE was associated with FGR, CO was low and PVR high, irrespective of gestational age. Importantly, in our study, pathological cases were similarly represented in numerical terms before and after 34 weeks, 24 and 21 cases, respectively.
The contradictory findings of previous studies, namely that gestational age is the determinant of hemodynamic profile in PE, may be explained because PE and FGR commonly coexist at early gestational ages 34 and FGR is uncommonly encountered in late PE.
14 PE is therefore more precisely defined by the presence or absence of FGR rather than by virtue of its gestational age at onset. We trace the origins of the categorization of early and late PE to a study on the sensitivity of second-trimester uterine artery Doppler for these complications, which was high for early but low for late disease. Interestingly, early PE was frequently found with FGR in that study.
In women with PE, with and without FGR, we found a significant positive association between CO Z score and birthweight normalized for gestation, which was no different before or after 34 weeks. We did not specifically select women with PE, with and without FGR, but instead recruited all comers and categorized FGR based on ultrasound and Doppler findings. Hence, there was no selection bias within women with PE because it might be argued that a larger fetus and placenta will drive a larger CO.
We previously reported that the incremental increase in maternal CO from prior to pregnancy to the midsecond trimester was positively associated with larger birthweight in normally grown babies 35 irrespective of the size of the fetus in the midtrimester. This suggests that fetal size on its own did not determine CO. A recent study in women with PE found that those with the lowest CO had the smallest babies. 15 There is strong, albeit circumstantial, evidence that CO may be at least in part responsible for birthweight, likely mediated through an effect on uteroplacental perfusion. Although this is tempting to speculate, we cannot infer causality from our results.
Of direct clinical relevance is that the current management of hypertension in pregnancy is exclusively based on a onesize-fits-all philosophy whereby blood pressure alone is the target of therapy, irrespective of the underlying aetiology. 36, 37 This approach does not distinguish between PE with FGR (low CO and high PVR) from PE without FGR (high CO). There is, however, a clear rationale in targeting therapy according to the underlying cardiovascular phenotype.
Drugs with beta-blocking activity are negatively chronotropic and reducing CO may be harmful in women with FGR in which the uteroplacental circulation is already impaired; previous studies have reported an association with small-forgestational-age babies. [38] [39] [40] We report that PE only was typically associated with high CO: for these women, a beta blocker might be preferable, whereas a drug leading to vasodilation primarily, such as a calcium channel antagonist, may be less effective.
Conversely, calcium antagonists are likely to be more effective in the high-PVR state that characterizes PE with FGR. Although a model using hemodynamic parameters to determine response to labetalol in gestational hypertension has been reported, 41 the effectiveness of antihypertensive agents with different modes of action has not. Indeed, if 42 with and without nitrovasodilators 43 and calcium antagonists 44 with reported improvement in maternal cardiovascular and/or fetal parameters. Arterial function was abnormal in PE only, FGR only, and the combination of both PE and FGR as assessed by AIx and PWV, irrespective of whether CO and PVR were increased or decreased. Aortic AIx is an index of wave reflection and may be considered as a measure of arterial function. [45] [46] [47] [48] Raised AIx is an important predictor of future cardiovascular risk 49 and in hypertensive patients an independent predictor of future myocardial infarction. 50 Although AIx is influenced by endothelial function, PWV describes aortic stiffness and is determined largely by the elastic component of large vessels. It is also known to be a reliable marker of cardiovascular risk in patients with hypertension. 51 The strength of this study is that detailed cardiovascular assessments were undertaken in women who were phenotyped according to accepted definitions for both PE and FGR. Importantly, our definition of FGR did not rely simply on fetal smallness 52 but required abnormal fetal umbilical artery Doppler. Our sample size allowed a high power to detect small differences in CO between the groups.
A weakness is that because our protocol required time-consuming examinations, not all women wanted to or could take part, in particular in which delivery or further therapy was being planned. This limited the number of women eligible for recruitment, but there was no attempt at selection other than through women consenting or otherwise for logistical and therapeutic reasons. Furthermore, although we intended to recruit women prior to starting antihypertensive treatment, these drugs were often started prior to hospital admission. Although we found no difference in CO and PVR within the PE only and PE and FGR groups, for those on antihypertensive treatment, the modest numbers within these groups preclude discrimination between small effect sizes in antihypertensive agents and the duration of therapy.
Although not being validated specifically in pregnancy, Innocor has been validated extensively in healthy populations and those with diseases, including chronic heart failure and during hemodynamic perturbation caused by exercise as a method of assessing cardiac output. [53] [54] [55] [56] In addition, our group has previously shown that this method has good reproducibility in pregnant women and is sensitive enough to detect longitudinal changes in CO both in very early pregnancy and throughout the gestational period. 27, 35, 57 All our participants were examined in a similar position, which limits any potential bias. Moreover because the gasrebreathing method is not operator dependent, there is no interobserver bias compared with echocardiography, which is the other widely used method. The Vicorder has been validated for use against SphygmoCor, which is the most widely used technique to assess pulse wave velocity. There is no agreed gold standard noninvasive technique to assess pulse wave velocity in pregnancy. 58 In summary, we found no evidence to support the categorization of PE of early and late as different disease processes, although early-onset PE was much more likely to be associated with FGR. The significance of this is that PE, which is not associated with FGR, has the same cardiovascular phenotype, namely high CO, whether it is diagnosed at 24 or 36 weeks. The presence of FGR was associated with high PVR, whether or not in combination with PE. Whether the abnormal hemodynamic profiles that we have observed in the distinct subtypes of PE, FGR, and PE combined with FGR are the cause of the clinical manifestation of hypertension and FGR or the effect of an inherent underlying maternal cardiovascular dysfunction is unclear.
This study raises an intriguing question as to whether the cardiovascular Original Research OBSTETRICS ajog.org dysfunction seen in pathological pregnancies is a result of maladaptation to the increased cardiovascular demands of pregnancy in a woman with normal cardiovascular function or is predisposed by an inherently abnormal prepregnancy cardiovascular status and its expression modulated through placental release of vasoactive substances. n Heart rate in controls and pathological outcome groups (median, IQR)
There was no difference in pathological outcome groups compared with controls.
FGR, fetal growth restriction; IQR, interquartile ratio; PE, preeclampsia.
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